Abstract

Members of the EAG K+ channel superfamily (EAG/Kv10.x, ERG/Kv11.x, ELK/Kv12.x subfamilies) are expressed in many cells and tissues. In particular, two prototypes, EAG1/Kv10.1/KCNH1 and ERG1/Kv11.1/KCNH2 contribute to both normal and pathological functions. Proliferation of numerous cancer cells depends on hEAG1, and in some cases, hERG. hERG is best known for contributing to the cardiac action potential, and for numerous channel mutations that underlie ‘long-QT syndrome’. Many cells, particularly cancer cells, express Src-family tyrosine kinases and SHP tyrosine phosphatases; and an imbalance in tyrosine phosphorylation can lead to malignancies, autoimmune diseases, and inflammatory disorders. Ion channel contributions to cell functions are governed, to a large degree, by post-translational modulation, especially phosphorylation. However, almost nothing is known about roles of specific tyrosine kinases and phosphatases in regulating K+ channels in the EAG superfamily. First, we show that tyrosine kinase inhibitor, PP1, and the selective Src inhibitory peptide, Src40-58, reduce the hERG current amplitude, without altering its voltage dependence or kinetics. PP1 similarly reduces the hEAG1 current. Surprisingly, an ‘immuno-receptor tyrosine inhibitory motif’ (ITIM) is present within the cyclic nucleotide binding domain of all EAG-superfamily members, and is conserved in the human, rat and mouse sequences. When tyrosine phosphorylated, this ITIM directly bound to and activated SHP-1 tyrosine phosphatase (PTP-1C/PTPN6/HCP); the first report that a portion of an ion channel is a binding site and activator of a tyrosine phosphatase. Both hERG and hEAG1 currents were decreased by applying active recombinant SHP-1, and increased by the inhibitory substrate-trapping SHP-1 mutant. Thus, hERG and hEAG1 currents are regulated by activated SHP-1, in a manner opposite to their regulation by Src. Given the widespread distribution of these channels, Src and SHP-1, this work has broad implications in cell signaling that controls survival, proliferation, differentiation, and other ERG1 and EAG1 functions in many cell types.

Highlights

  • The ‘ether-a-go-go’ gene family, which encodes alpha subunits of six-transmembrane domain voltage-gated K+ channels, has been divided into three sub-families: EAG, EAG-related gene (ERG) and EAG-like (ELK) K+ channels

  • We provided the first evidence of selective up-regulation of human ERG1 expression and function in primary leukemic cells and several hematopoietic cell lines, but not in proliferating noncancerous lymphocytes [12], and a similar result was seen in cells from acute myeloid leukemia patients [15]

  • We used patch-clamp analysis of cloned human ERG1 (hERG)/Kv11.1 channels to assess their regulation by Src-family tyrosine kinases, and by Src itself

Read more

Summary

Introduction

The ‘ether-a-go-go’ gene family, which encodes alpha subunits of six-transmembrane domain voltage-gated K+ channels, has been divided into three sub-families: EAG, EAG-related gene (ERG) and EAG-like (ELK) K+ channels. The two prototypes, EAG1/ Kv10.1/KCNH1 and ERG1/Kv11.1/KCNH2, normally have a restricted tissue expression, but are mutated or aberrantly expressed in several disease states. ERG1 has garnered enormous attention because many of its naturally occurring mutations, and numerous medications inhibit channel function and lead to life-threatening cardiac arrhythmias [8,9]. ERG1 is normally expressed in cardiac and vascular smooth muscle, the brain, thymus and adrenal gland [10], but its aberrant expression in several malignant cell types has aroused interest in its contributions to cancer [11,12,13,14,15]. We provided the first evidence of selective up-regulation of human ERG1 (hERG) expression and function in primary leukemic cells and several hematopoietic cell lines, but not in proliferating noncancerous lymphocytes [12], and a similar result was seen in cells from acute myeloid leukemia patients [15]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call